1 – 10 of 38
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Expanding the therapeutic potential of neuro(active)steroids : a promising strategy for hyperdopaminergic behavioral phenotypes
(
- Contribution to journal › Scientific review
- 2023
-
Mark
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease
(
- Contribution to journal › Article
- 2020
-
Mark
BDNF Overexpression Increases Striatal D3 Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia
(
- Contribution to journal › Article
- 2018
-
Mark
The serotonergic system in L-DOPA-induced dyskinesia : pre-clinical evidence and clinical perspective
(
- Contribution to journal › Article
- 2017
-
Mark
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats
(
- Contribution to journal › Article
- 2016
-
Mark
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
(
- Contribution to journal › Letter
- 2015
-
Mark
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
(
- Contribution to journal › Scientific review
- 2014
-
Mark
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
(
- Contribution to journal › Article
-
Mark
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
(
- Contribution to journal › Article
- 2013
-
Mark
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia
(
- Contribution to journal › Article